Overview

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Status:
Recruiting

Trial end date:
2026-11-30

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Revolution Medicines, Inc.